Get the Stockscreener App
29.21
2.60%
-0.78
After Hours:
29.55
0.34
+1.16%
Xencor Inc stock is traded at $29.21, with a volume of 930.15K.
It is down -2.60% in the last 24 hours and up +16.84% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$29.99
Open:
$30.08
24h Volume:
930.15K
Relative Volume:
0.44
Market Cap:
$2.17B
Revenue:
$97.36M
Net Income/Loss:
$-172.42M
P/E Ratio:
-12.71
EPS:
-2.2984
Net Cash Flow:
$-188.84M
1W Performance:
+13.04%
1M Performance:
+16.84%
6M Performance:
+151.38%
1Y Performance:
+99.11%
1-Day Range:
$28.92
$30.56
1-Week Range:
$27.76
$33.60
52-Week Range:
$10.38
$33.60
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
29.21 | 2.17B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Resumed | Wells Fargo | Overweight |
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor Is Maintained at Outperform by RBC Capital - Moomoo
Xencor, Inc. (XNCR) - Milk Road
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says - marketscreener.com
XENCOR Maintained by Wells Fargo -- Price Target Raised to $44.00 - GuruFocus
Truist raises Xencor stock price target on kidney cancer drug data - Investing.com
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell CarcinomaSlideshow - Seeking Alpha
RBC Raises Price Target on Xencor to $43 From $20, Keeps Outperform, Speculative Risk - marketscreener.com
Wells Fargo raises Xencor stock price target on kidney cancer data - Investing.com
Xencor stock surges on positive cancer drug trial data - Investing.com
Xencor soars 16% on encouraging early XmAb819 data (XNCR:NASDAQ) - Seeking Alpha
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway - Seeking Alpha
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer - Yahoo Finance
Why Is Xencor Stock Trading Higher Today?Xencor (NASDAQ:XNCR) - Benzinga
Set for RCC glory? Hard phase I data ‘cement’ Xencor - BioWorld News
Xencor stock hits 52-week high at 32.29 USD - Investing.com
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors - BioSpace
Xencor reports promising kidney cancer drug results, plans late-stage trial (XNCR:NASDAQ) - Seeking Alpha
Xencor reports 45.5% confirmed response at selected kidney-cancer dose - Mugglehead Investment Magazine
Xencor reports phase 1 data for cancer drug XmAb819 - Investing.com
Xencor, Inc. Estimates – NASDAQ:XNCR - TradingView
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (XNCR)What Are Researchers Saying About This Stock? - MarketBeat
Xencor to Host Webcast to Discuss Results Fro - Moomoo
Xencor schedules XmAb819 webcast: Wells Fargo targets Xencor stock at USD 30 - ad-hoc-news.de
symbol__ Stock Quote Price and Forecast - CNN
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update? - Yahoo Finance
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - BioSpace
Xencor to present phase 1 data for kidney cancer treatment - Investing.com
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance Australia
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
RBC keeps USD 20 target for Xencor stock ahead of ESMO data - ad-hoc-news.de
Truist raises target for Xencor stock to USD 29 - ad-hoc-news.de
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor Q3 2026 Earnings Date and Estimates - MarketBeat
Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR) - Seeking Alpha
Xencor stock fell 4.96 percent as targets diverged - AD HOC NEWS
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Wells Fargo & Company Initiates Coverage on Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock falls 3.52 percent as Truist lifts its target - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Climb 4.6%Should You Buy? - MarketBeat
Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial - MarketBeat
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com Nigeria
Truist Securities reiterates Buy rating on Xencor, $29 price target - TradingView
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Feigal Ellen | Director |
Jun 18 '26 |
Proposed Sale |
13.06 |
6,843 |
89,370 |
0 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
7,527 |
92,657 |
0 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,064 |
62,338 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Sale |
12.31 |
5,064 |
62,338 |
15,547 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
13,709 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Sale |
12.31 |
7,527 |
92,657 |
11,378 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
14,709 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO |
Apr 10 '26 |
Sale |
12.29 |
3,499 |
42,990 |
75,898 |
2.79%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):